

# Notice of References Cited

Application/Control No.

09/709,170

Applicant(s)/Patent Under  
Reexamination  
WARRELL ET AL.

Examiner

Terra Gibbs

Art Unit

1635

Page 1 of 3

## U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,214,986 B1 04-2001	06-1999	Bennett et al.	536/24.5
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author	Title	Date	Publisher	Edition or Volume	Pertinent Pages
	U	FI Raynaud et al.	Journal of Pharmacology and Experimental Therapeutics				Pharmacokinetics of C-3139, a Phosphorothioate Oligodeoxynucleotide... Intravenous Administration or Continuous Subcutaneous Infusion to Mice, Dec. 1996, Vol. 281, No. 1, pp. 420-427
	V	DE Lopes de Menezes et al.	Clinical Cancer Res.				Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2... Rree and Liposomal Doxorubicin, Jul. 2000, Vol. 6, pp. 2891-2902
	W	H Miyake et al.	Journal of the Natl. Cancer Institute				Chemosenitization and Delayed Androgen-Independent Recurrence... Antisense Bcl-2 Oligodeoxynucleotides, Jan. 2000, Vol. 92, No. 1, pp. 34-41
	X	FE Cotter et al.	Biochimica et Biophysica Acta	148	9		Human Bcl-2 antisense therapy for lymphomas, 1999, pp. 97-106

\*A copy of this reference is not being furnished with this Office action. (See MF-EP-S 707.05(a))  
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office  
 PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 13